Logo image of GRPH

GRAPHITE BIO INC (GRPH) Stock Fundamental Analysis

NASDAQ:GRPH - US38870X1046 - Common Stock

3.18 USD
-0.09 (-2.75%)
Last: 3/21/2024, 8:00:01 PM
3.22 USD
+0.04 (+1.26%)
After Hours: 3/21/2024, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GRPH. GRPH was compared to 547 industry peers in the Biotechnology industry. While GRPH has a great health rating, there are worries on its profitability. GRPH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRPH had negative earnings in the past year.
In the past year GRPH has reported a negative cash flow from operations.
In the past 5 years GRPH always reported negative net income.
In the past 5 years GRPH always reported negative operating cash flow.
GRPH Yearly Net Income VS EBIT VS OCF VS FCFGRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -66.14%, GRPH is doing worse than 63.44% of the companies in the same industry.
GRPH's Return On Equity of -67.90% is in line compared to the rest of the industry. GRPH outperforms 57.14% of its industry peers.
Industry RankSector Rank
ROA -66.14%
ROE -67.9%
ROIC N/A
ROA(3y)-38.38%
ROA(5y)N/A
ROE(3y)-40.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRPH Yearly ROA, ROE, ROICGRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

GRPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRPH Yearly Profit, Operating, Gross MarginsGRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for GRPH has been reduced compared to 1 year ago.
There is no outstanding debt for GRPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRPH Yearly Shares OutstandingGRPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GRPH Yearly Total Debt VS Total AssetsGRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 19.96 indicates that GRPH is not in any danger for bankruptcy at the moment.
GRPH's Altman-Z score of 19.96 is amongst the best of the industry. GRPH outperforms 91.84% of its industry peers.
GRPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.96
ROIC/WACCN/A
WACCN/A
GRPH Yearly LT Debt VS Equity VS FCFGRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 39.20 indicates that GRPH has no problem at all paying its short term obligations.
GRPH has a Current ratio of 39.20. This is amongst the best in the industry. GRPH outperforms 98.98% of its industry peers.
GRPH has a Quick Ratio of 39.20. This indicates that GRPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GRPH (39.20) is better than 98.98% of its industry peers.
Industry RankSector Rank
Current Ratio 39.2
Quick Ratio 39.2
GRPH Yearly Current Assets VS Current LiabilitesGRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GRPH have decreased strongly by -18.38% in the last year.
EPS 1Y (TTM)-18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GRPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.20% on average per year.
GRPH is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y81.37%
EPS Next 2Y34.67%
EPS Next 3Y21.95%
EPS Next 5Y9.2%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

GRPH Yearly Revenue VS EstimatesGRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 20M 40M 60M 80M 100M
GRPH Yearly EPS VS EstimatesGRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRPH Price Earnings VS Forward Price EarningsGRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRPH Per share dataGRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

GRPH's earnings are expected to grow with 21.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.67%
EPS Next 3Y21.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAPHITE BIO INC

NASDAQ:GRPH (3/21/2024, 8:00:01 PM)

After market: 3.22 +0.04 (+1.26%)

3.18

-0.09 (-2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2024-02-27/amc
Earnings (Next)N/A N/A
Inst Owners1.1%
Inst Owner Change0%
Ins Owners61.25%
Ins Owner Change0%
Market Cap184.47M
Analysts43.33
Price Target7.14 (124.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.01%
Min EPS beat(2)-204%
Max EPS beat(2)-52.03%
EPS beat(4)0
Avg EPS beat(4)-123.22%
Min EPS beat(4)-209.77%
Max EPS beat(4)-27.1%
EPS beat(8)3
Avg EPS beat(8)-61.61%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.14%
ROE -67.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.38%
ROA(5y)N/A
ROE(3y)-40.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 451.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 39.2
Quick Ratio 39.2
Altman-Z 19.96
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)505.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y81.37%
EPS Next 2Y34.67%
EPS Next 3Y21.95%
EPS Next 5Y9.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y30.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.3%
OCF growth 3YN/A
OCF growth 5YN/A